Hormonal drug shown to reduce prostate cancer risk in PIN cases
study from Orlando reports toremifene at 20 40 or 60 mg daily for one year lowered cancer development in men with prostatic intraepithelial neoplasia PIN. At one year 24.4 percent on drug vs 31 percent on placebo developed cancer with lowest dose most effective. larger trial enrolling.
MENTIONED IN THIS ARTICLE
Orlando
Fla
American Society Clinical Oncology
Len Lichtenfeld
American Cancer Society
Cancer Society
Harmon Eyre
United States
David Price
Shreveport
Price
Peter Greenwald
National Cancer Institute
Cancer drug shows promise in early trials
A new drug demonstrates early growth in treating prostate issues. Analysts note potential for preventing progression to cancer, as rising diagnoses affect up to 50,000 men annually with abnormal prostate growths. Prostate cancer remains the nation's leading major cancer with over 230,000 new cases and about 30,000 deaths projected this year.
MENTIONED IN THIS ARTICLE
United States
Also Mentioned on This Page
Lion
Veterans Affairs
Louisiana
Mississippi
Texas
Arkansas
Golf Shoes
Whiskey Rd
Aiken
IRS
The
Wall Street Journal
Dk Harris & Company
Taxexperts.com
Angela Fallaw-Zaremba
Waterloo St
Hobby Lobby
Paper Studio Ee
Popare Parts & More
Tsukineko
Ranger Olorbox
Pack Flor “Am Bricks
Hero Arts, Stampabilities
PSX
Hampton Arts
ALL
Crete
Calico
Ava
DMC
Ellen Originals
Timeless Tot
Eagle Loran & Unsek
Fairfield’ & Fashion Gear
Whiskey Road
James
Rockland
Daisy Kingdom
Asken
Hobbylobby.com